Riverview Trust Co Has $28,000 Stock Position in Baxter International Inc. (NYSE:BAX)

Riverview Trust Co grew its holdings in shares of Baxter International Inc. (NYSE:BAX) by 5,488.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 950 shares of the medical instruments supplier’s stock after buying an additional 933 shares during the quarter. Riverview Trust Co’s holdings in Baxter International were worth $28,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Pointe Capital Management LLC boosted its stake in Baxter International by 57.8% during the 4th quarter. Pointe Capital Management LLC now owns 10,978 shares of the medical instruments supplier’s stock valued at $320,000 after purchasing an additional 4,019 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Baxter International by 22.3% during the fourth quarter. Bank of New York Mellon Corp now owns 15,359,040 shares of the medical instruments supplier’s stock valued at $447,870,000 after buying an additional 2,803,920 shares during the last quarter. Handelsbanken Fonder AB boosted its position in shares of Baxter International by 33.8% during the fourth quarter. Handelsbanken Fonder AB now owns 291,102 shares of the medical instruments supplier’s stock valued at $8,489,000 after buying an additional 73,473 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Baxter International by 7.9% during the fourth quarter. New York State Common Retirement Fund now owns 476,248 shares of the medical instruments supplier’s stock valued at $13,887,000 after buying an additional 34,748 shares during the last quarter. Finally, Nicholas Hoffman & Company LLC. purchased a new position in Baxter International during the 4th quarter worth $907,000. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Price Performance

NYSE BAX opened at $34.50 on Friday. The company has a market cap of $17.65 billion, a PE ratio of -26.95, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31. The firm’s 50-day simple moving average is $31.23 and its two-hundred day simple moving average is $34.07. Baxter International Inc. has a 52 week low of $28.33 and a 52 week high of $44.01.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06. The business had revenue of $2.75 billion during the quarter, compared to analyst estimates of $2.67 billion. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. Research analysts predict that Baxter International Inc. will post 2.48 earnings per share for the current year.

Baxter International Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be issued a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 dividend on an annualized basis and a yield of 1.97%. Baxter International’s dividend payout ratio (DPR) is -53.13%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Baxter International in a report on Wednesday. They set a “buy” rating and a $42.00 price objective on the stock. Stifel Nicolaus cut their price target on shares of Baxter International from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Argus raised Baxter International from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. Barclays initiated coverage on Baxter International in a research report on Thursday, February 20th. They set an “overweight” rating and a $39.00 price target for the company. Finally, Citigroup decreased their target price on Baxter International from $37.00 to $35.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $39.00.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.